Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Starting soon · Phase 2 · Has a placebo group
Conditions studied: Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation, Corneal Endothelial Cell Loss, Corneal Endothelial Disorder, Corneal Endothelial Dystrophy 1, Endothelial Cell Loss, Corneal, Pseudophakic Bullous Keratopathy, Pseudophakic Bullous Keratopathy (PBK)
In brief
This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells \[mHCECs\]), compared with a placebo injection, in participants with corneal edema caused by corneal endothelial dysfunction.
Key facts
- Study ID
- NCT07729137
- Run by
- Emmecell
- People needed
- 121
- Starts
- 2026-09-01
- Expected to finish
- 2028-02-01
- Last updated by the study team
- 2026-07-29
Who can join
Age: 21 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Site 1 — Menlo Park, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.